{"id":11230,"date":"2020-07-17T00:00:00","date_gmt":"2020-07-17T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/","title":{"rendered":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE"},"content":{"rendered":"<p>Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9&nbsp; \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD (comme le l\u00e9nalidomide ou la pomalidomide), un inhibiteur du prot\u00e9asome (comme le bort\u00e9zomib ou le carfilzomib) et un anticorps monoclonal anti-CD38 (comme le daratumumab ou l\u2019isatuximab). Pour lire l&rsquo;article au complet, cliquez <strong><a href=\"https:\/\/www.myeloma.org\/blog\/good-news-fda-panel-votes-approve-belantamab-mafodotin\" target=\"_blank\" rel=\"noopener\">ici<\/a>&nbsp;<\/strong>(en anglais).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9&nbsp; \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11230","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11230"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11230\/revisions"}],"predecessor-version":[{"id":31317,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11230\/revisions\/31317"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}